Literature DB >> 14965222

Nanoparticles of biodegradable polymers for clinical administration of paclitaxel.

Si-Shen Feng1, Li Mu, Khin Yin Win, Guofeng Huang.   

Abstract

Paclitaxel is one of the best antineoplastic drugs found from nature in the past decades, which has been found effective against a wide spectrum of cancers including ovarian cancer, breast cancer, small and non small cell lung cancer, colon cancer, head and neck cancer, multiple myeloma, melanoma, and Kaposi's sarcoma. Like many other anticancer drugs, it has difficulties in clinical administration due to its poor solubility in water and most pharmaceutical reagents. In its current clinical application, an adjuvant called Cremophor EL has to be employed, which has been found to be responsible for many serious side effects. Nanoparticles of biodegradable polymers can provide an ideal solution to such an adjuvant problem and realize a controlled and targeted delivery of the drug with better efficacy and less side effects. With further development, such as particle size optimization and surface coating, nanoparticle formulation of paclitaxel can promote a new concept of chemotherapy to realize its full efficacy and to improve quality of life of the patients, which includes personalized chemotherapy, local chemotherapy, sustained chemotherapy, oral chemotherapy, chemotherapy across the blood-brain barrier, chemotherapy across the microcirculation barrier, etc. The present research proposes a novel formulation for fabrication of nanoparticles of poly(lactic-co-glycolic acid) (PLGA) by a modified solvent extraction/evaporation technique, in which natural emulsifiers, such as phospholipids, cholesterol and vitamin E TPGS are creatively applied to achieve high drug encapsulation efficiency, desired drug released kinetics, high cell uptake and high cytotoxicity. The nanoparticles composed of various recipes and manufactured under various conditions were characterized by laser light scattering (LLS) for size and size distribution, scanning electron microscopy (SEM) and atomic force microscopy (AFM) for morphological properties, X-ray photoelectron spectroscopy (XPS) and Fourier Transformation Infrared Spectroscopy (FTIR) for surface chemistry, zeta-potential for surface charge, and differential scanning calorimetry (DSC) for the thermogram properties. The drug encapsulation efficiency and the drug release kinetics under in vitro conditions were measured by high performance liquid chromatography (HPLC). It was found that these natural emulsifiers have great advantages for nanoparticle formulation of paclitaxel over the traditional macromolecular emulsifiers, such as polyvinyl alcohol (PVA). Nanoparticles of desired small size and narrow size distribution can be obtained. The drug encapsulation efficiency can be achieved as high as 100 %. The released kinetics can be made under control. The HT-29 cancer cell line experiment showed that after 24 hours of incubation, the cell mortality caused by the drug administered by such nanoparticle formulation could be more than 13 times higher than that caused by the free drug under similar conditions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14965222     DOI: 10.2174/0929867043455909

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  50 in total

1.  Recent advances in nanotechnology based drug delivery to the brain.

Authors:  Li-Na Lin; Qun Liu; Lei Song; Fang-Fang Liu; Jin-Xiu Sha
Journal:  Cytotechnology       Date:  2010-08-11       Impact factor: 2.058

2.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 3.  Nanoparticles: a promising modality in the treatment of sarcomas.

Authors:  Michiro Susa; Lara Milane; Mansoor M Amiji; Francis J Hornicek; Zhenfeng Duan
Journal:  Pharm Res       Date:  2010-05-27       Impact factor: 4.200

Review 4.  Drug transport to brain with targeted nanoparticles.

Authors:  Jean-Christophe Olivier
Journal:  NeuroRx       Date:  2005-01

5.  Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery.

Authors:  Huanyu Dou; Christopher J Destache; Justin R Morehead; R Lee Mosley; Michael D Boska; Jeffrey Kingsley; Santhi Gorantla; Larisa Poluektova; Jay A Nelson; Mahesh Chaubal; Jane Werling; James Kipp; Barrett E Rabinow; Howard E Gendelman
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

Review 6.  Hybrid nanoparticles for detection and treatment of cancer.

Authors:  Michael J Sailor; Ji-Ho Park
Journal:  Adv Mater       Date:  2012-05-21       Impact factor: 30.849

7.  Stereological analysis of the poly-(DL-lactide-co-glycolide) submicron sphere prepared by solvent/non-solvent chemical methods and centrifugal processing.

Authors:  M Stevanovic; N Ignjatovic; B Jordovic; D Uskokovic
Journal:  J Mater Sci Mater Med       Date:  2007-02-03       Impact factor: 3.896

Review 8.  Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies.

Authors:  Yumei Xie; Taryn R Bagby; M S Cohen; M Laird Forrest
Journal:  Expert Opin Drug Deliv       Date:  2009-08       Impact factor: 6.648

9.  The uptake and intracellular fate of PLGA nanoparticles in epithelial cells.

Authors:  Malgorzata S Cartiera; Katherine M Johnson; Vanathy Rajendran; Michael J Caplan; W Mark Saltzman
Journal:  Biomaterials       Date:  2009-02-20       Impact factor: 12.479

10.  Challenges and opportunities in developing nanoparticles for detoxification.

Authors:  Xin Qu; Maling Gou; Jana Zaidan; Kang Zhang; Shaochen Chen
Journal:  Nanomedicine (Lond)       Date:  2014-11       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.